¿Qué trae el futuro de Enzalutamida?

Previous Page

Next Page

Page Background

Enzalutamide

160 mg QD

+ LHRHa

(or orchidectomy)

until progression

n=1125

Metastatic prostate

cancer

ECOG 0–2

Commencing ADT

NSAA + LHRHa

(or orchidectomy)

until progression

R

1:1

•

STRATIFICATION:

–

High Volume Disease

(yes vs. no)

–

Early Use of Docetaxel

–

Concomitant “Anti-

Resorptive” Therapy

to Delay SRE,

–

Study Site

–

Co-Morbidities

Phase III Randomized study in mHSPC